Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM383 in mild Alzheimer's disease and MCI
NCT06619613Phase 1Recruiting
- Sponsor
- Keymed Biosciences
- Start
- Nov 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CM383 in Alzheimer's disease (AD) (4 arms), sponsored by Keymed Biosciences. Primary endpoint: Adverse event. Started Nov 2024; status: recruiting.
02
Drugs
CM383
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06619613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06619613.